louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05045365: Perfusion Assessment Using BOLD MRI and PBV in Endovascular Treatment of Peripheral Arterial Occlusive Disease
Official title: A Prospective Study: Perfusion Assessment Using Blood Oxygen Level Dependent Functional Magnetic Resonance Angiographic Imaging and Parenchymal Blood Volume Imaging in Endovascular Treatment of Peripheral Arterial Occlusive Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Peripheral Arterial Disease
Tissue Perfusion
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2021-09-16
Enrollment: 50
Sex: ALL
Minimum age (years): 35
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study was conducted in PAOD patients aged 35 to 80 years with clinical symptoms such as claudication, resting pain, or ulceration, who were intended for endovascular treatment. Computed tomographic angiography disclosed the occlusive lesion in their target lesion. Subject with complex infrapopliteal lesions was excluded in order to reduce the influence of other variables.

Brief summary: Current assessment of lower limb ischemia cannot reflect the location and degree of ischemia. Tissue perfusion assessment was used in the diagnosis and treatment of lower limb ischemia in this project, and the quantitative evaluation of ischemia degree was realized by using its advantages of quantitative analysis and perfusion imaging.


Eligibility criteria: Inclusion Criteria:

* Subject has been diagnosed as PAOD by symptom and imaging;
* Subject intends to take endovascular treatment in PUMCH;
* Subjects without heavy stenosis in infrapopliteal artery (stenosis\<30%), or with short length lesion(length≤5cm, stenosis≥30%);
* Age \> 35 and \< 80;
* Subject has been informed the study and has signed informed consent;

Exclusion Criteria:

* Subject with MRI contraindications or allergic to iodinated contrast medium;
* Subject underwent intervention therapy or angioplasty in target vessel within the last 3 months;
* Subject after stent implantation in superficial femoral artery;
* Subject with severe heart dysfunction, renal dysfunction, or cancer;

Primary outcomes:
measure: Perfusion of the index leg assessed by BOLD MRI before and after endovascular intervention.
timeFrame: 1 year
measure: Perfusion of the index leg assessed by PBV before and after endovascular intervention.
timeFrame: During operation
Secondary outcomes:
measure: The relationship between perfusion and function of the lower limb in PAOD patients
timeFrame: 1 year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT01657565: Appendectomy in Children Performed by Residents in the Era of Laparoscopic Surgery
Official title: Appendectomy in Children Performed by Residents in the Era of Laparoscopic Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intraabdominal Abscess
Wound Infection
Keywords: LOS
Ileus
Fever
reoperation
Lead sponsor: Odense University Hospital
Sponsor class: OTHER
First posted: 2012-08-06
Enrollment: 390
Sex: ALL
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: children 0-15 years of age having an appendectomy

Brief summary: Introduction: An increasing proportion of childhood appendicitis is treated with laparoscopic appendectomy (LA). The investigators wanted to elucidate the outcome of childhood appendicitis treated primarily by residents in a university hospital.

Material and methods: All children (age\<16 years) treated surgically with appendectomy in our department between January 2006 and January 2011 were retrospectively identified. Readmission, reoperation or postoperative length of stay (LOS) exceeding five days were considered as non-satisfactory outcomes.


Eligibility criteria: Inclusion Criteria:

* age below 16 years. operated on suspicion of appendicitis

Exclusion Criteria:

* appendectomy for causes other than suspicion of appendicitis

Primary outcomes:
measure: Surgical complications
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: Odense University Hospital
state: Fyn
Study officials:
References:
citation: Stilling NM, Fristrup C, Gabers T, Qvist N, Rasmussen L. Acceptable outcome after laparoscopic appendectomy in children. Dan Med J. 2013 Jan;60(1):A4564.
Clinical trial NCT01573065: HIV Testing and Brief Alcohol Intervention for Young Drinkers in the Emergency Department
Official title: Addressing HIV Risk in Young Unhealthy Alcohol Drinkers in the Emergency Department With Rapid HIV Testing and Brief Intervention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alcohol Consumption
Sexual Risk Behaviors
Keywords: alcohol consumption
sexual risk behaviors
young, unhealthy drinkers
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2012-04-06
Enrollment: 85
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study was to determine whether a brief counseling intervention coupled with rapid HIV testing was feasible and effective at decreasing alcohol consumption and sexual risk behaviors among young, unhealthy drinkers presenting to the Emergency Department.


Eligibility criteria: Inclusion Criteria:

* 18-40 years old;
* engaged in at least one sexual risk behavior in past 90 days;
* alcohol consumption greater than NIAAA guidelines for at-risk drinking;
* unknown or negative HIV status and willing to be tested;
* able to provide contact information for follow-up;
* able to provide written informed consent.

Exclusion Criteria:

* known HIV positive status;
* medically or psychiatrically unstable.

Primary outcomes:
measure: Feasibility
timeFrame: baseline and 2 month follow-up
Secondary outcomes:
measure: Alcohol consumption
timeFrame: baseline vs. 2 month follow-up
measure: Sexual risk behaviors
timeFrame: baseline vs. 2 month follow-up
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale New Haven Hospital Emergency Deparmtment
state: Connecticut
Study officials:
affiliation: Yale University
name: Lynn E Fiellin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06506565: Low-Dose Ketamine Infusion During Burn Wound Care
Official title: A Randomized, Placebo-Controlled, Double-Blind Evaluation of Low-Dose Ketamine Infusion During Burn Wound Care Procedures to Improve Pain Intensity and Reduce Opioid Consumption
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Burn
Pain
Dissociation
Opioid
Keywords: ketamine
burn
opioid
analgesia
Lead sponsor: University of Tennessee
Sponsor class: OTHER
First posted: 2024-07-17
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients will be randomly enrolled by blocks according to age, burn size, and opioid use history. Study treatment will occur for up to 7 days. Assignment will be to placebo or ketamine and all participants and staff will be blinded, except pharmacy. Each patient will receive standard of care fentanyl and midazolam during wound care regardless of study assignment.
Primary purpose: TREATMENT

Brief summary: The current standard of care (SOC) (i.e. fentanyl and midazolam) offers limited efficacy for preventing or relieving pain. Ketamine infusions may provide the benefits of analgesia, minimize adverse events, and reduce opioid use. The purpose of this study is to determine if adding a low dose ketamine infusion during wound care will safely provide pain relief for patients with burn injury.


Eligibility criteria: Inclusion Criteria:

* Admitted to burn service with thermal injury

Exclusion Criteria:

* unable/unwilling to consent within 72 hours
* unable to report NRS
* known contraindication to ketamine
* \< than 18 years of age
* pregnant
* incarcerated
* TBSA over 50 %

Primary outcomes:
measure: Analgesia
timeFrame: up to 7 days from enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Memphis
country: United States
facility: Regional One Health
state: Tennessee
Study officials:
References:
Clinical trial NCT03577665: Curative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer
Official title: A Phase II Study of Curative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Colorectal Cancer
Keywords: Liver Metastasis, Curative Proton Beam Therapy
Lead sponsor: National Cancer Center, Korea
Sponsor class: OTHER_GOV
First posted: 2018-07-05
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Proton alone therapy is performed

-\> 5 times a week, 7200 cGy / 15 fractions for 3 weeks total

Detailed description: This clinical trial is a prospective, single-organ, phase II clinical trial to evaluate the efficacy of curative proton therapy for liver metastasis of colorectal cancer diagnosed histologically as adenocarcinoma. Patients who meet the selection criteria should be selected, signed for consent, and treated 5 times a week for 7200 cGy / 15 fractions alone for 3 weeks.

Eligibility criteria: Inclusion Criteria:

1. Histologically diagnosed colon adenocarcinoma in primary or metastatic lesions..
2. If there is no other remote metastasis other than liver, or if there is, control is possible
3. If there are less than 2 liver metastatic lesions
4. If they refuse lung surgery or surgery is inappropriate (medically unsuitable for surgery due to surgery refusal, diabetes mellitus, high blood pressure, pulmonary disease, heart disease, etc., repeated surgery, poor systematic function, short disease-free period, etc.)

Exclusion Criteria:

1. Other histologic cancer other than adenocarcinoma of the colorectal
2. Colorectal cancer without primary lesion resection
3. If there is another remote metastasis and is not completely resected or regulated
4. If the patient has experience of other invasive cancer diagnosis within 5 years of colorectal cancer diagnosis
5. Pregnancy and women under lactation

Primary outcomes:
measure: 2-year local control ratio of the treated liver area
timeFrame: Time Frame: up to 2 years
Secondary outcomes:
measure: 5-year survival rate of treated patients
timeFrame: documented data of death, up to 5 years.
measure: 5-year disease-free survival rate of treated patients
timeFrame: documented date of progression or death, up to 5 years
Other outcomes:
Locations:
city: Goyang-si
country: Korea, Republic of
facility: National Cancer Center Korea
state: Gyeonggi-do
Study officials:
affiliation: National Cancer Center Korea(South Korea)
name: Dae Yong Kim, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04560465: Efficacy of Tranexamic Acid in Reducing Myomectomy Associated Blood Loss in Federal Teaching Hospital Abakaliki.
Official title: Efficacy of Tranexamic Acid in Reducing Myomectomy Associated Blood Loss in Federal Teaching Hospital Abakaliki
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: To Determine Efficacy of Tranexamic Acid in Reducing Blood Loss During Myomectomy
Keywords: Tranexamic acid, Myomectomy, Blood loss, Gravimetric
Lead sponsor: Alex Ekwueme Federal University Teaching Hospital
Sponsor class: OTHER
First posted: 2020-09-23
Enrollment: 59
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: two groups comprising of cases and control
Primary purpose: TREATMENT

Brief summary: to determine safety and efficacy of Tranexamic Acid in reducing blood loss during Myomectomy in our institution.

Detailed description: A double blinded randomized controlled trial in which cases were given 1000mg intravenous tranexamic acid into 1L of intravenous normal saline and control were given 10mls of placebo water for injection into same amount of intravenous fluid. outcome of both groups in terms of intraoperative blood loss, duration of surgery, postoperative packed cell volume and total blood loss with risk of blood transfusion were then determined.

Eligibility criteria: Inclusion Criteria:

* non-pregnant women with symptomatic myomas women with no known contraindication to tranexamic acid

Exclusion Criteria:

* past history of thromboembolic disorder, ischaemic heart disease, malignancy or liver disease

Primary outcomes:
measure: Average duration of surgery in each group
timeFrame: one year
measure: Mean intraoperative Blood loss
timeFrame: one year
measure: Postoperative Haemoglobin concentration
timeFrame: one year
Secondary outcomes:
measure: Blood Transfusion
timeFrame: One year
Other outcomes:
Locations:
city: Abakaliki
country: Nigeria
facility: AEFUTHA
state: Ebonyi
Study officials:
References:
Clinical trial NCT00226265: The Short Form-36: Pre- Versus Post-Surgical Administration in Cardiac Surgery Patients
Official title: The Short Form-36: Pre-vs. Post-Surgical Administration in Cardiac Surgery Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Bypass Grafting
Heart Diseases
Heart Valve Diseases
Keywords: Cardiac surgery patients
Quality of Life
Recall bias
Aortic valve replacement
Mitral valve replacement
Tricuspid valve replacement
Coronary artery bypass graft surgery
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
First posted: 2005-09-26
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cardiac Surgery Patients at New York Presbyterian Hospital-Weill Cornell Medical College

Brief summary: The purpose of this study is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.

Detailed description: The purpose of this study, is to determine whether the SF-36 can be administered reliably to cardiac surgery patients (two to three days) post-surgery, with the patient answering the questions of this survey from a pre-surgical perspective.

Eligibility criteria: Inclusion Criteria:

* Cardiac surgery patients who are between the ages of 18 and 100
* Are English speaking
* Able to give consent
* Undergoing cardiac surgery including (but not limited to):

  * Aortic valve replacement (AVR)
  * Mitral valve replacement (MVR)
  * Tricuspid valve replacement (TVR)
  * Coronary artery bypass graft (CABG).

Exclusion Criteria:

* Non-cardiac surgery patients

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: The New York Presbyterian Hospital-Weill Medical Center
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: Mary E Charlson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03507465: Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer
Official title: Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Breast Cancer
Keywords: letrozole
metronomic
capecitabine
neoadjuvant
chemotherapy
ER+/HER2-
Lead sponsor: Guangdong Provincial People's Hospital
Sponsor class: OTHER
First posted: 2018-04-25
Enrollment: 290
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Patients with ER+/HER2- breast cancer (presumably the luminal A subtype) could potentially avoid the standard chemotherapy use. Letrozole Plus Low-Dose Metronomic Capecitabine may offer similar efficacy and less toxicity to standard chemotherapy in ER+/HER2- breast cancer patients.


Eligibility criteria: Inclusion Criteria:

-women (age 18-70 years) with clinical T2-3 N0-1 M0 ER-positive (ER) allred score 4-8，and progesterone receptor-positive (PgR) ，HER2-negative adequate bone marrow reserve (WBC count, 3.5 \*109/L; platelets, 100\*109/L; hemoglobin, 10g/dL), hepatic function (AST/ALT bilirubin and alkaline phosphatase levels 1.25 the upper limit of normal value), and renal function (serum creatinine 1.25 the upper limit of normal value).

Luminal A/ lymph node positive breast cancer or Luminal B breast cancer patients

Exclusion Criteria:

* (a) male patients; (b) patients with inflammatory breast cancer or distant metastasis; (c) patients who were previously treated with chemotherapy, radiation therapy or prior treatment with AIs or antiestrogens for breast cancer; (d) patients with a second concomitant neoplasm; and (e) patients who could not meet the eligibility criteria.

Primary outcomes:
measure: objective response rate
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangdong General Hospital
state: Guangdong
Study officials:
References:
citation: Li WP, Zhu T, Hu MX, Yang M, Ji F, Gao HF, Yang CQ, Zhang LL, Cheng MY, Xu FP, Wang K. Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer. Neoplasma. 2020 Nov;67(6):1409-1415. doi: 10.4149/neo_2020_200130N96. Epub 2020 Jul 13.
Clinical trial NCT05344365: A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
Official title: An Open-label, Sequential Cohorts, Flexible Dose Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Iloperidone in Elderly Patients With Parkinson's Disease Psychosis (PDP)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Parkinson Disease Psychosis
Lead sponsor: Vanda Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2022-04-25
Enrollment: 0
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is an open-label, sequential cohorts, flexible dose study to evaluate the tolerability, safety and pharmacokinetics of iloperidone in elderly patients with Parkinson's disease psychosis (PDP).


Eligibility criteria: Inclusion Criteria:

* Willing and able to provide consent and willing to complete all aspects of the study.
* Male or female patients greater or equal to 65 years of age.
* Clinical diagnosis of idiopathic Parkinson's disease with a minimum duration of 1 year
* Psychotic symptoms for at least one month and actively experiencing psychotic symptoms each week during the month prior to screening

Exclusion Criteria:

* History of significant psychotic disorders prior to or concomitantly with the diagnosis of Parkinson's disease including, but not limited to, schizophrenia or bipolar disorder
* Current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the study

Primary outcomes:
measure: Assessment of safety and tolerability of iloperidone in patients with Parkinson's disease psychosis.
timeFrame: 8 days and 5 weeks
measure: Reduction in positive symptoms of Parkinson's disease psychosis.
timeFrame: 8 days and 5 weeks
measure: Pharmacokinetics of iloperidone and its metabolites following oral treatment with iloperidone.
timeFrame: 8 days and 5 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Petersburg
country: United States
facility: Vanda Investigational Site
state: Florida
Study officials:
References:
Clinical trial NCT06366165: Linking Special Care Dentistry Curriculum to Seemingly Irrelevant Comedy
Official title: The Effect of Using Seemingly Irrelevant Videos and Memes in Teaching Special Care Dentistry Curriculum
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Learning Problem
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-04-15
Enrollment: 700
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Testing the procedure of using a different mode of teaching medical content
Primary purpose: SCREENING

Brief summary: As Special care dentistry curriculum is very complicated and has a lot of details. Upon teaching it, the investigator will include memes and videos of movies and cartoons and will test the degree of retention of the information after years of passing the subject's exam.


Eligibility criteria: Inclusion Criteria:

* students in Ahram Canadian University.
* students who passed Special care dentistry course.
* students who were enrolled in the course from Fall 2021 to Summer 2023

Exclusion Criteria:

* Students who refused to answer the questionnaire

Primary outcomes:
measure: degree of retention of information
timeFrame: from 1 to 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Ahram Candian University
Study officials:
References: